Novanta Closes $1.2B Riverpoint Medical Acquisition, Adds $854.7M in Debt
NOVT sits 45% above its 52-week low of $98.27.
Summary
Novanta closed its $1.2 billion acquisition of Riverpoint Medical, funded by $616 million in new debt and cash, with a $250 million milestone payment due by early 2027. The deal is expected to add $0.18–$0.25 to adjusted EPS in 2027 and double medical consumables revenue.
Key Events · M&A and Partnerships · NOVT
-
Acquisition Closed
On July 23, 2026, the acquisition of Riverpoint Medical was finalized, with Novanta paying approximately $1.2 billion in cash and a $250 million milestone payment due by January 8, 2027.
-
Financing and Debt Impact
The transaction was funded by $616 million in borrowings under Novanta's revolving credit and delayed draw term loan facilities, plus cash on hand. As of July 22, 2026, consolidated debt rose to $854.7 million.
-
EPS Accretion Guidance
Management expects the acquisition to contribute $0.18 to $0.25 of adjusted EPS in 2027, the first full year after close, and to be immediately accretive to organic growth, adjusted gross margins, and adjusted EBITDA margins.
-
Strategic Transformation
Riverpoint Medical doubles Novanta's recurring medical consumables revenue to roughly $300 million and increases medical end-market exposure to 60% of total revenue, unlocking a $2 billion incremental addressable market.
Analysis · NOVT · Manufacturing
The acquisition of Riverpoint Medical is now complete, with Novanta paying approximately $1.2 billion in cash and a $250 million milestone payment due by January 2027. Funding came from $616 million in new borrowings and cash on hand, lifting consolidated debt to $854.7 million. Management expects the deal to be immediately accretive to organic growth, margins, and cash flows, contributing $0.18–$0.25 to adjusted EPS in 2027. This transaction transforms Novanta's medical consumables revenue to roughly $300 million and increases medical end-market exposure to 60% of total revenue, but the significant debt load introduces integration and leverage risks.
How filings like this one have moved
In the 30 days to Sep 16, 2026, 35.8% of the 1190 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.45%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NOVT was trading at $142.50 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $5B. The 52-week trading range was $98.27 to $171.85. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.